Terri Mujica’s Post

🧪 As the UK approaches a general election next month, The Association of the British Pharmaceutical Industry (ABPI) is challening the political parties to prioritise healthcare and life sciences. 🥼 The ABPI argues that unlocking the UK's healthcare industry potential will generate billions of pounds and create tens of thousands of new jobs, as well as providing better care to patients. 💊 This challenge follows a period of uncertainty for the biopharma industry. The group is urging politicians to help create a "joined-up life sciences ecosystem" equipped to deliver "rapid approvals" 🔬 You can find out more about the ABPI's manifesto in the article below #Biopharma #UKPharma #LifeSciences #UKLifeSciences

🧪 As the UK approaches a general election next month, The Association of the British Pharmaceutical Industry (ABPI) is challening the political parties to prioritise healthcare and life sciences. 🥼 The ABPI argues that unlocking the UK's healthcare industry potential will generate billions of pounds and create tens of thousands of new jobs, as well as providing better care to patients. 💊 This challenge follows a period of uncertainty for the biopharma industry. The group is urging politicians to help create a "joined-up life sciences ecosystem" equipped to deliver "rapid approvals" 🔬 You can find out more about the ABPI's manifesto in the article below #Biopharma #UKPharma #LifeSciences #UKLifeSciences

🧪 As the UK approaches a general election next month, The Association of the British Pharmaceutical Industry (ABPI) is challening the political parties to prioritise healthcare and life sciences. 🥼 The ABPI argues that unlocking the UK's healthcare industry potential will generate billions of pounds and create tens of thousands of new jobs, as well as providing better care to patients. 💊 This challenge follows a period of uncertainty for the biopharma industry. The group is urging politicians to help create a "joined-up life sciences ecosystem" equipped to deliver "rapid approvals" 🔬 You can find out more about the ABPI's manifesto in the article below #Biopharma #UKPharma #LifeSciences #UKLifeSciences

🧪 As the UK approaches a general election next month, The Association of the British Pharmaceutical Industry (ABPI) is challening the political parties to prioritise healthcare and life sciences. 🥼 The ABPI argues that unlocking the UK's healthcare industry potential will generate billions of pounds and create tens of thousands of new jobs, as well as providing better care to patients. 💊 This challenge follows a period of uncertainty for the biopharma industry. The group is urging politicians to help create a "joined-up life sciences ecosystem" equipped to deliver "rapid approvals" 🔬 You can find out more about the ABPI's manifesto in the article below #Biopharma #UKPharma #LifeSciences #UKLifeSciences

Pharma companies are working to reduce drug development timelines. Grant Swart, GM at Mayne Pharma Services, reveals how Australian CDMOs are achieving this through the nation's tax incentives, streamlined regulations, and a thriving clinical trial ecosystem. Read the full article here: https://lnkd.in/eJGS3sdu #CDMO #Australia #Pharma #Lifesciences

Keir Milburn from Abundance (UK) proposes public-common partnership to build an alternative pharmaceutical infrastructure. 🏥  “It is Important is to have transparent finances, re-invested into the industry and not in the pockets of people who are already rich.”  Milburn makes clear that to move away from the current model, we will need a strategy. Now it is Big Pharma who has the resources and they put extra pressure by claiming that there is no alternative. But one by one, we can build a public-common network and we can achieve a democratic way of organizing the medicines production by putting our own demands. 🏥🔥 #Publicpharmaeurope

Some important insights into the legal and policy developments likely to affect the UK's life sciences sector in the coming months.

The UK’s #LifeSciences sector, valued at £90 billion, occupies a pivotal position in the landscape of innovation and economic growth. Recently, the UK Government unveiled a substantial £650 million “war chest” aimed at bolstering the life sciences industry. Simultaneously, the #EuropeanUnion’s pharmaceutical regulatory framework is poised for significant transformations. Against this backdrop, our article delves into the critical legal and policy developments that will shape the UK life sciences sector in the coming months. From empowering innovation to fostering growth, these initiatives promise a dynamic and forward-looking future. Read more here: https://lnkd.in/ecXWr4wJ #LifeSciences #Innovation #Regulation #UKSector

Below an interesting read by Alexander Schuhmacher et al, evidencing the continued decline in #pharma R&D productivity. Apart from some exceptions, the gap between output (newly approved drugs) and input (R&D spend) is widening for big pharma. So much of our public debate circles around high prices for innovative treatments, with the justification of high R&D expenditures to be recuperated. We absolutely need to continue to encourage medical #innovation and make R&D risk worthwhile; our lives depend upon it. However, given the productivity trend, we do need to make sure that R&D dollars are spent responsibly. R&D #efficiency is not just vital to the pharma business model, it is paramount for affordable healthcare as a whole.

🚀 Adapting Gross-to-Net to the Inflation Reduction Act 📈 Join me on CommercialBytes as I sit down with Philip Sclafani, a Partner in PwC's Pharmaceutical & Life Sciences practice, and Rashima Vatnani, a Senior Manager in PwC’s Sales and Pricing practice, who provided valuable insights into the latest on the Inflation Reduction Act and impacts to the Healthcare and Pharmaceutical landscape.  During this episode we covered main provisions of the IRA, the complexities introduced by the IRA to the 340B drug pricing program, and strategies for industry players to adapt and innovate in response to these changes. Don't miss out on this insightful discussion that sheds light on how the IRA is reshaping our industry and what it means for all stakeholders involved. #Healthcare #Pharma #InflationReductionAct #340B #CommercialBytes #PwC #PharmaceuticalIndustry #HealthcareInnovation #DrugPricing